G-CSF for menopause
A study is assessing the efficacy of repeated G-CSF administration for hot flashes and vasomotor symptoms in postmenopausal women, but no efficacy results are reported.
Hypothesized mechanism
Mechanism not yet characterized in the substrate.
This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.
How the score was reached, for this pair
The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 4 of 10 overall, a emerging reading, from a direct rated emerging in strength.
The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.
Scored for women. Evidence generated in women (female population, ~100% female). (band F1, ×1.00).
Corroboration
The single source is a clinical study/trial description ('A Study of the Safety and Effect of Repeated Administration of G-CSF on Hot Flashes in Postmenopausal Women') with no results reported. A single primary study with no outcome data scores 0; there is no independent corroboration.
Rigor
The claim describes a study assessing efficacy and safety of repeated G-CSF administration, but the design (RCT vs. observational, sample size, controls) is not specified and only the intent to assess is stated. Without confirmed RCT design or results, this is treated as a small/unspecified trial at best.
Specificity
The intervention (G-CSF) and condition (hot flashes/vasomotor symptoms in postmenopausal women, i.e., menopause) are both named directly in the quote. Both drug and condition are explicit.
Plausibility
No mechanism is described in the verified claim for how G-CSF would affect hot flashes or vasomotor symptoms. The text only states an intent to assess efficacy, with no asserted or evidenced biological rationale.
Consistency
Only a single source with no reported results is available, so there is nothing to compare for directional agreement. Per scoring rules, a single study is scored 1 (not penalized).
Layers not covered for this pair
Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.
More on the sex-specific pharmacokinetics layer and its sources →Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.
More on the cycle-phase layer and its sources →Source evidence · what the pipeline ingested
These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).
Every source below belongs to this signal’s evidence arm, Direct research. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.
- 1assess the efficacy and safety of repeated administration of G-CSF for the treatment of hot flashes and vasomotor symptoms in women with naturally-occurring or surgically induced menopause ClinicalTrials.gov · NCT03640754 ↗
- 2assess the efficacy and safety of repeated administration of G-CSF for the treatment of hot flashes and vasomotor symptoms in women with naturally-occurring or surgically induced menopause ClinicalTrials.gov · NCT03640754 ↗
These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.
The primary sources and pipelines this evidence is drawn from →